Could a heart pill beat long-COVID exhaustion?
NCT ID NCT05697640
First seen Jan 29, 2026 · Last updated May 25, 2026 · Updated 18 times
Summary
This study tests whether vericiguat, a drug already used for heart failure, can improve physical function and reduce fatigue in people with post-COVID syndrome. About 104 adults aged 18-50 will take either vericiguat or a placebo for 10 weeks. The goal is to see if the drug helps them move better and feel less tired.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for POST-COVID ME/CFS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Charité - Universitätsmedizin Berlin
Berlin, State of Berlin, 10117, Germany
Conditions
Explore the condition pages connected to this study.